JAZZ PHARMACEUTICALS INC 4
4 · JAZZ PHARMACEUTICALS INC · Filed Jun 6, 2007
Insider Transaction Report
Form 4
TANANBAUM JAMES B
Director
Transactions
- Conversion
Common Stock
[F1][F2]2007-06-06+660,849→ 660,849 total(indirect: By Prospect Venture Partners II, L.P.) - Conversion
Common Stock
[F1][F3]2007-06-06+10,063→ 10,063 total(indirect: By Prospect Associates II, L.P.) - Conversion
Common Stock
[F1][F2]2007-06-06+554,801→ 554,801 total(indirect: By Prospect Venture Partners II, L.P.) - Conversion
Common Stock
[F1][F3]2007-06-06+8,448→ 8,448 total(indirect: By Prospect Associates II, L.P.) - Conversion
Stock A Preferred Stock
[F1][F2]2007-06-06−660,849→ 0 total(indirect: By Prospect Venture Partners II, L.P.)→ Common Stock (660,849 underlying) - Conversion
Stock A Preferred Stock
[F1][F3]2007-06-06−10,063→ 0 total(indirect: By Prospect Associates II, L.P.)→ Common Stock (10,063 underlying) - Conversion
Stock B Preferred Stock
[F1][F2]2007-06-06−554,801→ 0 total(indirect: By Prospect Venture Partners II, L.P.)→ Common Stock (554,801 underlying) - Conversion
Stock B Preferred Stock
[F1][F3]2007-06-06−8,448→ 0 total(indirect: By Prospect Associates II, L.P.)→ Common Stock (8,448 underlying)
Footnotes (3)
- [F1]The Issuer's Preferred Stock automatically converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The shares are owned by Prospect Venture Partners II, L.P. ("PVP II"), which is under common control with Prospect Associates II, L.P. ("PA II"). Prospect Management Co. II, L.L.C. ("PMC II") serves as the sole general partner of PVP II. James B. Tananbaum, M.D. is a Managing Director of PMC II and shares voting and investment power over the shares held by PVP II. The Reporting Person disclaims beneficial ownership of the shares held by PVP II except to the extent of his proportionate pecuniary interest therein.
- [F3]The shares are owned by PA II. PMC II serves as the sole general partner of PA II. James B. Tananbaum, M.D. is a Managing Director of PMC II and shares voting and investment power over the shares held by PA II. The Reporting Person disclaims beneficial ownership of the shares held by PA II except to the extent of his proportionate pecuniary interest therein.
Signature
/s/ Dave Markland, Attorney in Fact for James B. Tananbaum, M.D.|2007-06-06